PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November17, 2017, Chau Q. Khuong stepped down from the Board of Directors (the “Board”) of Pieris Pharmaceuticals, Inc. (the “Company”). Mr.Khuong’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr.Khuong previously served on the Company’s Audit Committee and Compensation Committee. Mr.Khuong will be replaced on the Audit Committee by Julian Adams, M.D., a Board member since July 2016.
Item 5.02: Regulation FD Disclosure.
The Board has appointed James Geraghty, one of the Company’s current directors, to serve as Chairman of the Board, replacing Mr.Khuong.Mr.Geraghty has served on the Board since May 2017 and is an industry leader with thirty years of strategic and leadership experience, including more than twenty years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies.
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a copy of the press release announcing Mr.Geraghty’s appointment as Chairman of the Board.
The information set forth under this “Item 5.02. Regulation FD Disclosure,” including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 5.02: Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release datedNovember21, 2017 announcing Mr. Geraghty’s appointment as Chairman of the Board.
PIERIS PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d486201dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors BOSTON,…To view the full exhibit click here
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.